No Picture
Trading Ideas

Visa (V) Stock is a ‘Sell’ as Markets Bounce Back

Distillate Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Distillate Capital’s U.S. Fundamental Stability & Value (U.S. FSV) strategy posted a return of -19.39% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned -19.60% in the same quarter. You should […] …read more […]

No Picture
Trading Ideas

Microsoft Stock is a ‘Sell’ as Markets Bounce Back

Distillate Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Distillate Capital’s U.S. Fundamental Stability & Value (U.S. FSV) strategy posted a return of -19.39% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned -19.60% in the same quarter. You should […] …read more […]

No Picture
Trading Ideas

3 “Strong Buy” Penny Stocks That Offer Massive Potential Gains

The stock market is heating up, and some Wall Street bulls are turning even more positive. Among those adapting an increasingly bullish approach is Stifel’s Head of Institutional Equity Strategy, Barry Bannister, who believes the worst is behind us, freeing up the S&P 500 to continue its ascent. Previously calling for an aggressive rebound right before the market’s March lows, he now projects that by the end of August, the S&P 500 will hit 3,250, reflecting an 8% rise from current levels.“We now raise our S&P 500 price target to 3,250 by Aug-30, 2020 (in 3 months), supported by economic …read more […]

No Picture
Trading Ideas

AstraZeneca partners with Oxford Biomedica to expand COVID-19 vaccine manufacturing capacity

The experimental shot is also being produced by the Serum Institute of India, the world’s largest manufacturer of vaccines by volume, and AstraZeneca is in talks with several governments and global partners to increase production. Oxford Biomedica said on Thursday it signed a one-year clinical and commercial supply agreement with AstraZeneca to provide multiple batches of the vaccine, called AZD1222, and that the majority of the batches would be produced throughout 2020. Last month, Oxford Biomedica said it joined a consortium, including the Jenner Institute, that came together for possible large-scale manufacturing of AZD1222. …read more […]